Nicotine addiction through a neurogenomic prism: ethics, public health, and smoking.
Studies are under way to examine the neurogenetic factors contributing to smoking behaviors. The combined approaches of genomics, molecular biology, neuroscience, and pharmacology are expected to fuel developments in pharmacogenetics, to create new genetic tests, and ultimately to provide the basis for innovative strategies for smoking cessation and prevention. The emergence of a neurogenomic understanding of nicotine addiction is likely to induce fundamental changes in popular, clinical, and public health views of smoking, which could significantly shape existing practices and policies to reduce tobacco use. Still a nascent area of research, nicotine addiction provides an excellent case study through which to anticipate key ethical and policy issues in both behavioral genetics and the neurogenomics of addictive behaviors.
Caron
Lorraine
L
Agence d'évaluation des technologies et des modes d'intervention en santé, Montreal, Canada.
Karkazis
Katrina
K
Raffin
Thomas A
TA
Swan
Gary
G
Koenig
Barbara A
BA
D016739:Behavior, Addictive / Q000235:genetics / Q000517:prevention & control; D032984:Ethics, Research; D006801:Humans; D009488:Neurosciences / Q000592:standards; D009538:Nicotine / Q000009:adverse effects; D010597:Pharmacogenetics; D011322:Primary Prevention / Q000592:standards; D011640:Public Policy; D012107:Research Design; D012907:Smoking / Q000235:genetics; D016540:Smoking Cessation / Q000379:methods; D000074606:Smoking Prevention; D014029:Tobacco Use Disorder / Q000235:genetics / Q000517:prevention & control
D009538:Nicotine